Pharma industry veteran VK Singh has joined Ahmedabad based Cadila Pharmaceuticals as the Chief Operating Officer (COO) of its Chemical Strategic Business Unit, which mainly focuses on Active Pharma Ingredients (APIs) manufactured in India. Singh will be based out of Ahmedabad.

VK as he is fondly known as in the industry, is a Chemical Engineer from IIT Kanpur, and an MBA from the Indian Institute of Foreign Trade, New Delhi. He has experience of over 20 years in the pharma industry, and the last ten years in leading and transforming organisations.

He was last associated as Chief Business Officer with Strides Pharma Science. Prior to that, he was associated with leading pharma companies such as Emcure Pharmaceuticals, RPG Life Sciences, Ethypharm India, and Ranbaxy in various roles.

Singh performed a general management function leading mid-sized pharma companies over the last decade, and has a wide experience, spanning across formulations, drug delivery, APIs, business development, corporate strategy and mergers and acquisitions. His strength is leading international business with a focus on regulated markets.

“Cadila Pharmaceuticals is one of the fastest-growing pharma companies in the country and is at an inflection point in its growth trajectory. I am excited about being part of this journey. I look forward to working closely with the team at Cadila Pharmaceuticals to chart out new growth opportunities,” Singh said on his association with Cadila Pharmaceuticals.

Cadila Pharmaceuticals Ltd (www.cadilapharma.com) is one of the largest privately-held pharmaceutical companies in India. It has recently concluded and cleared US FDA inspection successfully in February 2020. Over the past six decades, Cadila Pharmaceuticals has been engaged in the development and manufacturing of affordable medicines and in making them available for patients across the world. Its innovation-driven drug discovery processes ensure the health and well-being of people around the world.